Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 2
1955 1
1956 1
1957 1
1958 2
1961 2
1962 1
1963 3
1964 1
1965 2
1967 1
1968 1
1984 1
1986 1
1990 1
1992 1
1995 2
1999 1
2000 1
2001 2
2002 5
2003 1
2004 4
2005 1
2006 1
2007 4
2008 5
2009 4
2010 11
2011 6
2012 7
2013 6
2014 9
2015 7
2016 9
2017 7
2018 11
2019 5
2020 12
2021 16
2022 16
2023 18
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Results by year

Filters applied: . Clear all
Page 1
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
Mizuta H, Okada K, Araki M, Adachi J, Takemoto A, Kutkowska J, Maruyama K, Yanagitani N, Oh-Hara T, Watanabe K, Tamai K, Friboulet L, Katayama K, Ma B, Sasakura Y, Sagae Y, Kukimoto-Niino M, Shirouzu M, Takagi S, Simizu S, Nishio M, Okuno Y, Fujita N, Katayama R. Mizuta H, et al. Among authors: katayama r. Nat Commun. 2021 Feb 24;12(1):1261. doi: 10.1038/s41467-021-21396-w. Nat Commun. 2021. PMID: 33627640 Free PMC article.
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K, Singh M, Chin E, Parks M, Lee D, DiCecca RH, Lockerman E, Huynh T, Logan J, Ritterhouse LL, Le LP, Muniappan A, Digumarthy S, Channick C, Keyes C, Getz G, Dias-Santagata D, Heist RS, Lennerz J, Sequist LV, Benes CH, Iafrate AJ, Mino-Kenudson M, Engelman JA, Shaw AT. Gainor JF, et al. Among authors: katayama r. Cancer Discov. 2016 Oct;6(10):1118-1133. doi: 10.1158/2159-8290.CD-16-0596. Epub 2016 Jul 18. Cancer Discov. 2016. PMID: 27432227 Free PMC article.
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer.
Katayama Y, Yamada T, Tanimura K, Tokuda S, Morimoto K, Hirai S, Matsui Y, Nakamura R, Ishida M, Kawachi H, Yoneda K, Hosoya K, Tsuji T, Ozasa H, Yoshimura A, Iwasaku M, Kim YH, Horinaka M, Sakai T, Utsumi T, Shiotsu S, Takeda T, Katayama R, Takayama K. Katayama Y, et al. Among authors: katayama r. NPJ Precis Oncol. 2023 Jan 26;7(1):12. doi: 10.1038/s41698-023-00350-7. NPJ Precis Oncol. 2023. PMID: 36702855 Free PMC article.
Targeting Podoplanin for the Treatment of Osteosarcoma.
Takemoto A, Takagi S, Ukaji T, Gyobu N, Kakino M, Takami M, Kobayashi A, Lebel M, Kawaguchi T, Sugawara M, Tsuji-Takayama K, Ichihara K, Funauchi Y, Ae K, Matsumoto S, Sugiura Y, Takeuchi K, Noda T, Katayama R, Fujita N. Takemoto A, et al. Among authors: katayama r. Clin Cancer Res. 2022 Jun 13;28(12):2633-2645. doi: 10.1158/1078-0432.CCR-21-4509. Clin Cancer Res. 2022. PMID: 35381070 Free PMC article.
Hitting the target in HER2 mutant cancers.
Katayama R. Katayama R. Nat Cancer. 2022 Jul;3(7):785-786. doi: 10.1038/s43018-022-00386-x. Nat Cancer. 2022. PMID: 35883002 No abstract available.
183 results